MT-228
MT-228 (BPN-0026709) is a selective and blood-brain barrier permeable non-muscle myosin II inhibitor. MT-228 markedly improves tolerability by selectively targeting NMIIB (KI = 1.5 μM) over CMII (KI = 17 μM), and the sequence of SmMll MD is 83.6% identical to that of NMllB. MT-228 shows long-lasting efficacy in animal models of stimulant use disorder[1].
Product Specifications
CAS Number
2404652-24-8
Product Name Alternative
BPN-0026709
UNSPSC
12352005
Target
Myosin
Related Pathways
Cytoskeleton
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Purity
99.9
Smiles
O=C1[C@@]2(O)C(N(C3=CC(OC)=NC=C3)CC2)=NC4=C1C=C(C)C(C)=C4
Molecular Formula
C19H19N3O3
Molecular Weight
337.37
References & Citations
[1]Radnai L, et al. Development of Clinically Viable Non-Muscle Myosin II Small Molecule Inhibitors with Broad Therapeutic Potential. bioRxiv [Preprint]. 2024 Oct 12:2024.10.07.617018.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
133277-ML405 100 µL
SGTA (Small Glutamine-rich Tetratricopeptide Repeat-containing Protein alpha, Alpha-SGT, Vpu-binding protein, UBP, SGT, SGT1) (MaxLight 405) discontinued
Sign In for Pricing
View Details 